Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

Similar articles for PubMed (Select 17455991)

1.

Following the script: how drug reps make friends and influence doctors.

Fugh-Berman A, Ahari S.

PLoS Med. 2007 Apr;4(4):e150. Review. No abstract available.

2.

GSK nixing physician dollars: other companies not to follow suit.

Berger E.

Ann Emerg Med. 2014 Jun;63(6):19A-21A. No abstract available.

PMID:
24967442
3.

Drug firms cut doctors' fees for drug talks.

McCarthy M.

BMJ. 2014 Mar 7;348:g2021. doi: 10.1136/bmj.g2021. No abstract available.

PMID:
24607478
4.

Strong medicine for doctors: 'Just say no' to gifts from drug reps, a Columbia U. physician urges his colleagues.

Mangan KS.

Chron High Educ. 2004 Jan 9;50(18):A28-9. No abstract available.

PMID:
15287140
5.

Missed opportunities in pharma?

Owens J.

Nat Rev Drug Discov. 2004 Oct;3(10):893. No abstract available.

PMID:
15497248
6.

The long and winding road.

[No authors listed]

Nat Rev Drug Discov. 2005 Jun;4(6):443. No abstract available.

PMID:
15959946
7.

Jonathan K. C. Knowles discusses the impact of pharmacogenomics on market segmentation.

Knowles JK.

Nat Rev Drug Discov. 2004 Oct;3(10):822. No abstract available.

PMID:
15497246
8.

The pharmaceutical industry and the medical profession.

Phatak A.

Issues Med Ethics. 1998 Oct-Dec;6(4):131-2. No abstract available.

PMID:
16267942
9.

Soft targets: nurses and the pharmaceutical industry.

Jutel A, Menkes DB.

PLoS Med. 2008 Feb;5(2):e5. doi: 10.1371/journal.pmed.0050005. Review. No abstract available.

10.

Wisdom of the crowd.

[No authors listed]

Nature. 2005 Nov 17;438(7066):281. No abstract available.

PMID:
16292279
11.

As doctor writes prescription, drug company writes a check.

Harris G.

N Y Times Web. 2004 Jun 17:A1, A19. No abstract available.

PMID:
15290802
12.

[Is it pertinent to investigate the relations between physicians and the drug industry].

Moliner J, Mozota J, Abad JM, Casaña L, Júdez D, Rabanaque MJ.

Rev Calid Asist. 2009 Apr;24(2):72-9. doi: 10.1016/S1134-282X(09)70656-6. Spanish.

PMID:
19426930
13.

Drug samples: friend or foe?

Resneck J Jr.

J Drugs Dermatol. 2002 Sep;1(2):124. No abstract available.

PMID:
12847734
14.

[Commercial effectiveness of the pharmaceutical industry. Industry cost-effectiveness and customers value].

Mur Martí J, Vilardell Molas M.

Med Clin (Barc). 2004 May 22;122(19):753-7. Spanish. No abstract available.

PMID:
15171911
15.

Payments to doctors in Australia are to be scrutinised after marketing tactics are exposed.

Moynihan R.

BMJ. 2011 Oct 18;343:d6714. doi: 10.1136/bmj.d6714. No abstract available.

PMID:
22008810
16.

The marketplace can't give us the drug safety data we need.

Avorn J.

MedGenMed. 2007 Feb 9;9(1):29. No abstract available.

17.

Nurses and the pharmaceutical industry: part 1.

Olsen DP.

Am J Nurs. 2009 Jan;109(1):36-9. doi: 10.1097/01.NAJ.0000344035.19274.fc. No abstract available.

PMID:
19112263
18.

Relationship between the pharmaceutical industry and pharmacy practitioners: undue influence?

Haines ST, Dumo P.

Am J Health Syst Pharm. 2002 Oct 1;59(19):1871-4. No abstract available.

PMID:
12374076
19.

Excess in the pharmaceutical industry.

Angell M.

CMAJ. 2004 Dec 7;171(12):1451-3. No abstract available.

20.

To sell their drugs, companies increasingly rely on doctors.

Hensley S, Martinez B.

Wall St J (East Ed). 2005 Jul 15:A1,A2. No abstract available.

PMID:
16134281
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk